Acute lymphoblastic leukaemia
L Pagliaro, SJ Chen, D Herranz, C Mecucci… - Nature Reviews …, 2024 - nature.com
Acute lymphoblastic leukaemia (ALL) is a haematological malignancy characterized by the
uncontrolled proliferation of immature lymphoid cells. Over past decades, significant …
uncontrolled proliferation of immature lymphoid cells. Over past decades, significant …
Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions
I Abou Dalle, N Moukalled, J El Cheikh, M Mohty… - Leukemia, 2024 - nature.com
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) constitutes a
distinctive cytogenetic entity associated with challenging outcomes, particularly in adult …
distinctive cytogenetic entity associated with challenging outcomes, particularly in adult …
[HTML][HTML] How to manage Philadelphia-positive acute lymphoblastic leukemia in resource-constrained settings
Simple Summary Remarkable strides have been performed in the treatment of adults
diagnosed with Philadelphia-positive lymphoblastic leukemia (Ph+ ALL) through the …
diagnosed with Philadelphia-positive lymphoblastic leukemia (Ph+ ALL) through the …
Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia
Y Chalandon, P Rousselot, S Chevret, JM Cayuela… - Blood, 2024 - ashpublications.org
We previously demonstrated that a reduced-intensity chemotherapy schedule can safely
replace hyper-CVAD (cyclophosphamide-vincristine-doxorubicin [Adriamycin] …
replace hyper-CVAD (cyclophosphamide-vincristine-doxorubicin [Adriamycin] …
[HTML][HTML] MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications
V Tran, K Salafian, K Michaels, C Jones… - Current Hematologic …, 2024 - Springer
Abstract Purpose of Review Measurable residual disease (MRD) is integral in the
management of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia …
management of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia …
Leveraging health care technology to improve health outcomes and reduce outcome disparities in AYA leukemia
JC Molina, S Rotz - Hematology, 2023 - ashpublications.org
Significant improvements have occurred for adolescent and young adult (AYA) B-cell acute
lymphoblastic leukemia (B-ALL) patients following the widespread adoption of “pediatric …
lymphoblastic leukemia (B-ALL) patients following the widespread adoption of “pediatric …
An Update on the Management of Advanced Phase Chronic Myeloid Leukemia
NJ Short, J Senapati, E Jabbour - Current hematologic malignancy reports, 2023 - Springer
Abstract Purpose of Review While most patients with chronic myeloid leukemia (CML)
present in a chronic phase and are expected to have a normal life expectancy, some …
present in a chronic phase and are expected to have a normal life expectancy, some …
Posttreatment positivity of BCR:: ABL1 in acute lymphoblastic leukemia: Should we keep track?
J Zuna, L Hovorkova, J Krotka… - American journal …, 2023 - pubmed.ncbi.nlm.nih.gov
Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?
Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep …
Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep …
Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens
NJ Short, H Kantarjian, E Jabbour - Leukemia & Lymphoma, 2024 - Taylor & Francis
Blinatumomab and inotuzumab ozogamicin (INO) are both active in relapsed/refractory B-
cell acute lymphoblastic leukemia (ALL) and improve outcomes compared with conventional …
cell acute lymphoblastic leukemia (ALL) and improve outcomes compared with conventional …
[HTML][HTML] Is next-generation sequencing the future of measurable residual disease assays for Philadelphia chromosome-positive acute lymphoblastic leukemia?
NJ Short, H Kantarjian, E Jabbour - Expert review of hematology, 2024 - Taylor & Francis
The outcomes of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic
leukemia (ALL) have significantly improved over the past several years, due largely to the …
leukemia (ALL) have significantly improved over the past several years, due largely to the …